Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 138

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS

Blood blood.2024025897.

https://doi.org/10.1182/blood.2024025897

Published: 2024

Includes: Supplemental data

Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Blood (2024) 144 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2024-200333

Published: 2024

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2024-200958

Published: 2024

Journal Articles

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Jeffrey V Matous, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E Mason, Thomas Renaud, Gurdeep Parmar

Blood (2024) 144 (Supplement 1): 1975.

https://doi.org/10.1182/blood-2024-199773

Published: 2024

Journal Articles

Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions

David M Foureau, Oscar Berlanga, Cindy Varga, Barry Paul, Shebli Atrash, Christopher Ferreri, Semegne Hiruy, Lawrence J. Druhan, Ariel Bell, Phillip Holmes-Snowden, Gabriella Lakos, Peter M. Voorhees, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 1964.

https://doi.org/10.1182/blood-2024-208695

Published: 2024

Journal Articles

Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Fan Wang, Heiko Babel, Vanessa Schmitt, Muhammad Erfan Uddin, Muhamed Baljevic, Peter M. Voorhees, Cesar Rodriguez, Shaji Kumar, Hira Mian, Anders Erik Svensson, Chetasi Talati, Sven Mensing, Rajeev M Menon, Benjamin Engelhardt, Akshanth R Polepally

Blood (2024) 144 (Supplement 1): 1994.

https://doi.org/10.1182/blood-2024-206054

Published: 2024

Journal Articles

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Blood (2024) 144 (Supplement 1): 3792.5.

https://doi.org/10.1182/blood-2024-210957

Published: 2024

Journal Articles

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

Darryl Chang, Myra Robinson, Rupali Bose, Hamid Ehsan, Arunkumar Krishnan, Shanice Borden, Peter M. Voorhees, Barry Paul, Manisha Bhutani, Cindy Varga, Christopher Ferreri, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2287.

https://doi.org/10.1182/blood-2024-209358

Published: 2024

Journal Articles

Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center

Semegne Hiruy, Myra Robinson, Shebli Atrash, Barry Paul, Reed Friend, Cindy Varga, Christopher J Ferreri, Mauricio Pineda-Roman, Peter M. Voorhees, Manisha Bhutani

Blood (2024) 144 (Supplement 1): 3769.

https://doi.org/10.1182/blood-2024-202137

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab

Brittany Grossi, Nina Kim, Monal Kohli, Bingcao Wu, Emeka Umeh, Dee Lin, Gideon Aweh, Emily Achter, Laura Hester, Sian Walker, Christina Hearty, Peter M. Voorhees

Blood (2024) 144 (Supplement 1): 3783.

https://doi.org/10.1182/blood-2024-208509

Published: 2024

Journal Articles

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Blood (2024) 144 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2024-206357

Published: 2024

Journal Articles

Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy

Shebli Atrash, James Symanowski, Sarah Norek, Monica Plott, Cecilia Flynn, Kelly Bumgarner, Darynne Rhinehardt, Xhevahire Begic, Robin Cox, Barry Paul, Cindy Varga, Reed Friend, Christopher Ferreri, Manisha Bhutani, Mauricio Pineda-Roman, Peter M. Voorhees

Blood (2024) 144 (Supplement 1): 4751.

https://doi.org/10.1182/blood-2024-205957

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7854.

https://doi.org/10.1182/blood-2024-210841

Published: 2024

Journal Articles

Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution

Cindy Varga, Ferdous Ahmed, Marvin Knight, Manisha Bhutani, Barry Paul, Shebli Atrash, Peter M. Voorhees, Christopher Ferreri

Blood (2024) 144 (Supplement 1): 4720.

https://doi.org/10.1182/blood-2024-204361

Published: 2024

Journal Articles

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Blood (2024) 144 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2024-204257

Published: 2024

Journal Articles

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 897.

https://doi.org/10.1182/blood-2024-203409

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 934.

https://doi.org/10.1182/blood-2024-205989

Published: 2024

NARROW

Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions

Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Supportive Care Utilization in Patients with Multiple Myeloma-a Single Center Retrospective Study

Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only